Ingenol mebutate gel for actinic keratosis

New England Journal of Medicine

Volumn 366, Issue 11, 2012, Pages 1010-1019

  Lebwohl, Mark ^a   Swanson, Neil ^b   Anderson, Lawrence L ^c   Melgaard, Anita ^d   Xu, Zhenyi ^e   Berman, Brian ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Dermatology Associates of Tyler   (United States)

^d Department of Biostatistics and Data Management ^*  (Denmark)

^e LEO PHARMA A S   (Denmark)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INGENOL MEBUTATE; PLACEBO;

ACTINIC KERATOSIS; AGED; APPLICATION SITE INFECTION; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; ARTICLE; CLINICAL EFFECTIVENESS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EROSION; ERYTHEMA; EYE DISEASE; EYELID EDEMA; GEL; HEADACHE; HEART DISEASE; HUMAN; INTOXICATION; LOCAL SKIN REACTION; MAJOR CLINICAL STUDY; MEDIASTINUM DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERIORBITAL EDEMA; PIGMENT DISORDER; PRIORITY JOURNAL; PUSTULE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCAR FORMATION; SCORING SYSTEM; SKIN DISEASE; SKIN SWELLING; SKIN ULCER; THORAX DISEASE;

EID: 84863229834     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1111170     Document Type: Article

References (16)

1. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008;18:651-9.
2. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. J Am Acad Dermatol 1995;32:95-8.
3. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007;157:Suppl 2: 34-40. (Pubitemid 350179628)
4. Green AC, Beardmore GL. Home treatment of skin cancer and solar keratoses. Australas J Dermatol 1988;29:127-30.
5. Ramsay JR, Suhrbier A, Aylward JH, et al. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br J Dermatol 2011;164:633-6.
6. Challacombe JM, Suhrbier A, Parsons PG, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 2006;177:8123-32. (Pubitemid 44846331)
7. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 2004;64:2833-9. (Pubitemid 38500622)
8. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesionspecific immune response. J Am Acad Dermatol 2011 November 4 (Epub ahead of print).
9. Signorini DF, Leung O, Simes RJ, et al. Dynamic balanced randomization for clinical trials. Stat Med 1993;12:2343-50. (Pubitemid 24007153)
10. Swanson N, Stein Gold L, Larsson T, Melgaard A. Long-term follow-up studies of ingenol mebutate gel for the treatment of actinic keratosis. In: Program and abstracts of the 2011 Fall Clinical Dermatology Conference, Las Vegas, October 27-30, 2011. abstract.
11. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146:94-100. (Pubitemid 34158414)
12. Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001;40:709-13. (Pubitemid 34023642)
13. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004;50:714-21. (Pubitemid 38580548)
14. Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebocontrolled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010;62:582- 90.
15. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002;70:22-9.
16. Yentzer B, Hick J, Williams L, et al. Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch Dermatol 2009;145: 203-5.